STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Alvotech and STADA add to strategic alliance through denosumab partnership
iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital Management and Boxer Capital — both existing investors — are leading the financing. iTeos added that its Phase 2 test of belrestotug plus dostarlimab in metastatic PD-L1 high non-small cell lung cancer “exceeded pre-defined efficacy criteria” at an interim assessment. Its stock $ITOS was up about 40% on Friday morning. — Jaimy Lee & Ayisha Sharma
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
NEW YORK, Dec 22 (Reuters) - UnitedHealth Group (UNH.N) agreed on Friday to sell its Brazilian health insurance operator Amil to businessman Jose Seripieri Filho, two sources with knowledge of the matter said.
STADA and Alvotech receive positive CHMP opinion for ustekinumab biosimilar
Speculation that Stada Arzneimittel may be looking for a buyout has largely been confirmed after the company’s CEO said as much in a recent German-language news story.